Venue: **Exhibition, Ground Level**

Presentation: **Monday 1 July, 12:30-14:30**

The Poster Exhibition is open from Mon 1 - Wed 3 July from 10:00 to 18:30. Late breaker posters will be displayed for the duration of the conference.

Authors from **track A and track C** late breaker posters will stand by their posters on Monday, 1 July between 12:30 and 14:30 to answer questions and provide further information on their study results.

Track A > **Basic Sciences**

PE01-03 **Strategies to target and eradicate reservoirs**

MOLBPE01 **Teaching new dogs new tricks: an *in vitro* model of autologous HIV-1 immunotherapy induces CTL from naïve precursors in subjects on ART**

K. Smith, R. Mailliard, D. Ratner, W. Jiang, P. Gupta, J. Mullins, C. Rinaldo

United States

MOLBPE02 **Maraviroc (MVC) intensification can activate NFkB through CCR5 and the expression of its target genes in resting CD4+ T cells in suppressed HIV-1-infected patients**

N. Madrid-Elena, B. Hernandez-Novoa, L. Garcia-Bermejo, S. Moreno

Spain

MOLBPE03 **Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T cells**

F. Wightman, H.K. Lu, A.E. Solomon, S. Saleh, A.N. Harman, A.L. Cunningham, L. Gray, M. Churchill, P.U. Cameron, A.E. Dear, S.R. Lewin

Australia

PE04 **Early virus-host interactions**

MOLBPE04 **Galectin-3 promotes virus budding and cell-to-cell transmission of HIV-1**

S.-F. Wang, C.-H. Tsao, Y.-T. Lin, M.-L. Chiang, F.-C. Chien, P. Chen, D. Hsu, Y.-M. Chen, H.-Y. Chen, F.-T. Liu

Taiwan, Province of China

PE05 **Other innate immune responses**

MOLBPE05 **cART reduces antibody-dependent cellular cytotoxicity to HIV: implications for therapeutic vaccines**

V. Madhavi, S. Jegaskanda, R. Center, F. Ana Sosa Batiz, J. Ananworanich, D. Cooper, A. Kelleher, D. Hsu, M. Kramski, S. Kent

Australia

PE06 **B cells and alterations**

MOLBPE06 **b12 knock-in mouse mice and bNAb cell lines as vaccine models for vaccine antigen evaluation**

T. Ota, C. Doyle-Cooper, A. Cooper, K. Doores, M. Aoki-Ota, W. Schief, R. Wyatt, D. Burton, D. Nemazee

United States

PE07-08 **Correlates and biomarkers of disease progression**

MOLBPE07 **Evidence of innate immune activation in HIV-1-infected elite controllers**

E.M.P. Wilson, S. Krishnan, V. Sheikh, A. Rupert, D. Mendoza, S.A. Migueles, I. Sereti

United States

MOLBPE08 **Elevated hepcidin concentrations at HIV diagnosis are associated with increased mortality**

P.A. Minchella, A.E. Armitage, B. Darboe, M.W. Jallow, G. Thomas, A. Jaye, J.M. McDermid, A.M. Prentice

United States

PE09 **Correlates of protection**

MOLBPE09 **Thrombospondin: a new biomarker for the progressive and non-progressive HIV disease**

V. Conceicao, N.K. Saksena

Australia

PE10-11 **HIV drug development**

MOLBPE10 **Efficient inhibition of HIV-1 replication by a triple combination lentiviral vector**

Y. Chen

Hong Kong

MOLBPE11 **BIT225, a novel Inhibitor of HIV-1 release from HIV-1 reservoirs of the myeloid lineage**

J. Wilkinson, C. Luscombe, G. Ewart, S. Kerr, N. Tanliang, W. Ratanasuwan, R. Murphy, M. Miller

Australia

PE12 **HIV-hepatitis virus interactions**

MOLBPE12 **Evolution of HIV infection in romanian patients with HBV coinfection since early childhood**

O. Streinu-Cercel, A. Streinu-Cercel, A.M. Tudor, A. Negut, A. Streinu-Cercel

Romania

Track C > **Prevention Science**

PE25 **Reproductive choices and interventions for HIV infected women and uninfected women including discordant couples**

MOLBPE25 **Barriers to postnatal family planning in the prevention of mother to child transmission of HIV program in rural Zambia**

S. Okawa, M. Changala, N. Ishikawa, H. Kapyata, P. Kalichini, S. Kobayashi, M. Kahula, C. Siachiwena, S. Muvuma, C. Msiska, I. Sikazwe, C. Moyo, K. Komada, S. Miyano, S. Tsuzuki, T. Kato, M. Jimba, G. Syakantu

Japan

PE26 **Barriers and facilitators to adherence to biomedical HIV prevention strategies**

MOLBPE26 **Measuring the use of antiretroviral medications as PrEP at the population level**

I. Zablotska, A. Grulich, G. Prestage

Australia

PE27-28 **Pre-exposure prophylaxis (systemic)**

MOLBPE27 **HIV-associated risk behaviour among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok, Thailand**

S. Vanichseni, M. Martin, P. Suntharasamai, U. Sangkum, P. Mock, M. Leethochawalit, S. Chiamwongpaet, S. Kittimunkong, L. Paxton, M. Curlin, K. Choopanya, Bangkok Tenofovir Study Group

Thailand

MOLBPE28 **The association between risk perception and adherence in the FEM-PrEP clinical trial**

A. Corneli, M. Wang, K. Agot, K. Ahmed, L. Olang'o, S. Makatu, J. Lombaard, M. Malahleha, L. Van Damme, FEM-PrEP Study Group

South Africa

PE29 **Pre- and post-exposure prophylaxis (topical) / microbicides**

MOLBPE29 **Antiviral properties of zinc acetate enhance the protective efficacy of the MIV-150/ZA/CG microbicide gel**

M. Hsu, O. Mizenina, N. Jean-Pierre, K. Levendosky, S. Seidor, J. Bess, J.D. Lifson, T. Zydowsky, M. Robbiani, J. Fernández Romero

United States

PE30 **Treatment as prevention**

MOLBPE30 **Undetectable viral load is associated with increased unprotected anal intercourse in gay serodiscordant couples**

B.R. Bavinton, F. Jin, I. Zablotska, G. Prestage, A. Grulich, The Opposites Attract Study Team

Australia

PE31 **Male circumcision**

MOLBPE31 **Prevalence and associated factors of anticipated risk compensation after taking up male circumcision among heterosexual male sexually transmitted diseases patients in China**

Z. Wang, J. Lau

Hong Kong

PE32-33 **Novel approaches for HIV testing**

MOLBPE32 **A factorial randomized trial of abbreviated HIV counseling and testing and enhanced referral to care in Uganda**

R. Wanyenze, M. Kamya, R. Fatch, H. Mayanja-Kizza, S. Baveewo, G. Szekeres, D. Bangsberg, T. Coates, J. Hahn

Uganda

MOLBPE33 **Finger-stick whole blood HIV1/2 self tests showed higher sensitivity than oral fluid-based candidates**

M. Jaspard, G. Le Moal, M. Roncato, D. Plainchamp, A. Langlois, P. Camps, L. Hocqueloux, A. Guigon, T. Prazuck

France

PE35 **Gender sensitization, empowerment and violence reduction**

MOLBPE35 **Patriarchal villages in South Africa mobilised to break the cycle of endemic and culturally sanctioned human rights' abuses: a structured intervention with sustained sexual and gender-based violence impacts**

C. Carty, F. Nicholson, T. Mukaro, E. Marilele, P. Nare, M. Sibara

South Africa

PE36 **Second and third generation surveillance strategies**

MOLBPE36 **Enhanced surveillance to evaluate the national response to HIV: an interim analysis of a nationally representative HIV serologic survey in Kenya**

W. Maina, D. Kimanga, I. Mohamed, M. Muro, M. Obudho, G. Kichamu, P. Mureithi, J. Muttunga, W. Akhwale, S. Schwarcz, A. Kim

Kenya

Venue: **Exhibition, Ground Level**

Presentation: **Tuesday 2 July, 12:30-14:30**

The Poster Exhibition is open from Mon 1 - Wed 3 July from 10:00 to 18:30. Late breaker posters will be displayed for the duration of the conference.

Authors from **track B and track D** late breaker posters will stand by their posters on Tuesday, 2 July between 12:30 and 14:30 to answer questions and provide further information on their study results.

Track B > **Clinical Sciences**

PE13 **Staging, progression of disease: impact of co-factors / viral clade / tropism / genetic factors/ gender/age/ coinfection**

TULBPE13 **HBV and HCV co-infection: long term immunological, virological and survival outcomes following cART**

Y.-M.A. Chen, Y.-H. Chen, Y.-T. Lin, P.-L. Lim, E. Yunihastuti, S. Kiertiburanakul, T. Merati, R. Chaiwarith, P. Phanuphak, P.-C. Li, N. Kumarasamy, S. Vonthanak, R. Ditangco, C.K. Lee, K.V. Nguyen, S. Pujari, A. Kamarulzaman, F. Zhang, T.T. Pham, J.Y. Choi, S. Oka, P. Kantipong, M. Mustafa, W. Ratanasuwan, M. Law, N. Durier

Taiwan, Province of China

PE14 **Viral resistance testing in clinical trials and practice**

TULBPE14 **Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China**

X. Zou, X. Chen, H. Tian, A.B. Williams, H. Wang, J. Chiarella, M.J. Kozal

China

PE15 **Hepatitis B and D**

TULBPE15 **Detectable HBV DNA in plasma but no HBV drug resistance in HIV/HBV co-infected patients on tenofovir-containing antiretroviral therapy**

J. Audsley, A. Avihingsanon, G. Matthews, S. Bowden, M. Littlejohn, L. Yuen, S. Locarnini, S. Lewin, J. Sasadeusz

Australia

PE16 **Hepatitis C**

TULBPE16 **What is the minimum cost per person to cure HCV?**

A. Hill, S. Khoo, B. Simmons, N. Ford

United Kingdom

PE17-18 **Clinical trials - phase III/post-licensing**

TULBPE17 **Dolutegravir is non-inferior to raltegravir and shows durable response through 96 weeks: results from the SPRING-2 trial**

F. Raffi, H. Jaeger, D. Motta, H. Albrecht, E. Belonosova, J.M. Gatell, J.-G. Baril, P. Domingo, C. Brennan, S. Almond, S. Min, SPRING-2 Study Group

France

TULBPE18 **Efficacy of tenofovir disoproxil fumarate/emtricitabine and tenofovir disoproxil fumarate/ lamivudine both in combination with efavirenz in antiretroviral-naïve, HIV-1-infected Zambians**

L.B. Mulenga, A. Mwango, C. Moyo, A. Mweemba, P. Musonda, P.L. Mulenga, I. Sikazwe, P. Katayamoyo, M. Limbada, S. Nzala, B. Andrews, F. Goma, C.B. Moore, N. Lambwe, S. Lakhi

Zambia

PE19 **Management strategies for treatment experienced patients**

TULBPE19 **Phase 3 assessment of dolutegravir (DTG) 50mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled**

G. Nichols, A. Lazzrin, F. Maggiolo, G. Penco, D. Wright, A. Mills, R. Grossberg, J.-M. Molina, J. Durant, G. Pialoux, S. Moreno, M.M. Doroana, M. Ait-Khaled, J. Huang, S. Min, C. Vavro, J. Yeo

United States

PE20 **Non-pregnant women including menopause, contraception**

TULBPE20 **Reproductive choices and family planning for women living with HIV in Swaziland: implementing the Jadelle Implant**

S. Perry, P. Swamy, A. Mwanymba, G.A. Preidis, N. Motsa, H.N. Sarero

Swaziland

PE21 **Diagnosis of HIV disease including early diagnosis in infancy**

TULBPE21 **Presumptive diagnosis of HIV infection in HIV-exposed infants and children under 18 months of age at a paediatric HIV centre in Tanzania´s lake zone**

S. Shea, J. Bradford, M. Mgawe, P. Chacky, A. Kayabu, M. Minde, J. Sanders, J. Bisimba, L. Mwita, M. Tolle

Tanzania, United Republic of

PE22 **Clinical trials and antiretroviral therapy for children**

TULBPE22 **PRINCE 1: 48 week safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral treatment-naïve and -experienced infants and children 3 months to 6 years of age**

R. Strehlau, A. Liberty, A. Pena Donati, P. Martinez Arce, J. Lissens, R. Yang, D. Butcher, S. Biguenet

United States

PE23-24 **Therapeutic vaccine and immune based therapy trials**

TULBPE23 **Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002)**

S. Matsushita, K. Yoshimura, T. Maeda, T. Murakami, KD-1002 Principal Investigators and The Protocol Team of Quintiles

Japan

TULBPE24 **Effects of IL-7 on cell-associated DNA in blood and rectal tissue: the ERAMUNE 01 study**

C. Katlama, S. Lambert, F. Lecardonnel, L. Papagno, G. Tambussi, B. Clotet, M. Youle, D. Costagliola, B. Autran, ERAMUNE-01 Study Group

France

Track D > **Operations and Implementation Research**

PE37 **Integrating prevention interventions with care/treatment services including new models of service delivery**

TULBPE37 **Expansion of access to PMTCT services in Nigeria through the decentralization of services to PHCs: the Hygeia Foundation experience**

M. Akinseye, O. Adenusi, O. Adebiyi, I. Umoru, O. Olakunle, W. Ugwoeruchukwu

Nigeria

PE38-39 **Provider and facility characteristics that determine clinical and prevention outcomes**

TULBPE38 **Further investigation to address the details of the poor outcome based on prospective cohort study of HIV-infected patients in rural area of Zambia**

T. Kato, Y. Yasutaka, K. Komada, S. Miyano, J. Watara, D. Christphoer, A. Mwango, G. Syakantu

Japan

TULBPE39 **Tanzanian experience: treatment outcomes after 7 years of a national public-driven HIV care and treatment program**

B. Kilama, J. Todd, F. Ewings, R. Josiah, A. Ramadhani, D. Mmbando

Tanzania, United Republic of

PE40 **Interventions to improve long-term adherence to treatment and biomedical prevention**

TULBPE40 **Adherence to antiretroviral therapy in adolescents living with HIV: a meta-analysis**

S.-H. Kim, S. Gerver, S. Fidler, H. Ward

United Kingdom

PE41 **Strategies to increase linkage to HIV care among those in need**

TULBPE41 **A rapid ethnographic assessment of current barriers to care before the implementation of mobile health clinics for ART scale up in rural Mozambique, 2013**

A. Schwitters, P. Lederer, L. Zilversmit, P. Samo Gudo, I. Ramiro, K. Jobarteh

United States

PE42-43 **Interventions to improve retention in the PMTCT cascade, including early infant diagnosis**

TULBPE42 **Improved uptake of institutional birth and early infant HIV diagnosis following SMS reminders among PMTCT patients in Mozambique: a randomized control trial**

D. Joseph-Davey, W. Ponce, O. Augusto, D. Traca, C. de Palha de Sousa

Mozambique

TULBPE43 **Texting improves testing: a randomized controlled trial of text messaging to increase postpartum clinic attendance and rates of early infant diagnosis of HIV**

T.A. Odeny, E.A. Bukusi, C.R. Cohen, C.S. Camlin, K. Yuhas, R.S. McClelland

Kenya

PE44 **Feasibility, cost effectiveness and impact of various strategies to integrate HIV interventions with other health programs (TB, RCH/MCH, NCD, IMNCI, malaria)**

TULBPE44 **Integration of cervical cancer screening using visual inspection with acetic acid and cryotherapy treatment into HIV/AIDS services in rural districts of western Uganda**

J. Ekong, C. Kakande, M. Mutabazi, H. Kakande, F. Castano, T. Emeetai, J. Kabalangira, M. Kaur, R. Lulua

Uganda

PE45

	Scale up of early infant diagnosis and paediatric treatment: feasibility and operational issues
TULBPE45	**Factors associated with testing for early infant diagnosis of HIV in rural Zambia**
	S. Tsuzuki, M. Changala, C. Msiska, S. Okawa, Y. Yasutaka, K. Komada, N. Ishikawa, S. Miyano, G. Syakantu
	Japan
PE46	**Strategies to increase access to viral load measurements**
TULBPE46	**The OPP-ERA Project: open polyvalent platforms for a sustainable access to quality and affordable viral load testing in resource-limited settings**
	C. Rouzioux, OPP-ERA Study Group (ANRS, ESTHER, FEI, Sidaction and Solthis)
	France
PE47	**Optimizing the use of clinical lab monitoring in low resources setting**
TULBPE47	**Understanding health centre testing practices in Malawi: baseline study for implementation of sample transport programme**
	J. Brown, D. Ofarrell, J. Kandulu, R. Mwenda, K. Nichols, C. Porter
	South Africa
PE48	**National and international financing initiatives, including cross national comparisons of financing initiatives**
TULBPE48	**An analytical approach for assessing return on investment of HIV responses and planning efficient resource allocations: results from 11 countries in Asia and eastern Europe**
	D. Wilson, C. Kerr, A. Shattock, A. Yakusik, L. Zhang, J. Reyes, Q. Pham, K. Razali, A. Hoare, E. Chow, A. Jamaludin, J. Cheah, K. Ian Iu, H.-H. Thein, K. Henderson, M. Gorgens, R. Gray
	Australia